Esperion Therapeutics (ESPR) Revenue Growth (1y) (2020 - 2026)
Esperion Therapeutics (ESPR) Revenue Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.34% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.91% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -11.85% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.62% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 7.85% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 42.25% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 14.92% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 23.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.25% |
| Dec 31, 2025 | 143.73% |
| Sep 30, 2025 | 69.10% |
| Jun 30, 2025 | 11.58% |
| Mar 31, 2025 | -52.81% |
| Dec 31, 2024 | 114.30% |
| Sep 30, 2024 | 52.00% |
| Jun 30, 2024 | 186.33% |
| Mar 31, 2024 | 466.14% |
| Dec 31, 2023 | 71.38% |
| Sep 30, 2023 | 78.97% |
| Jun 30, 2023 | 36.86% |
| Mar 31, 2023 | 29.16% |
| Dec 31, 2022 | 22.19% |
| Sep 30, 2022 | 31.72% |
| Jun 30, 2022 | -53.66% |
| Mar 31, 2022 | 136.10% |
| Dec 31, 2021 | 59.79% |
| Sep 30, 2021 | 275.92% |
| Jun 30, 2021 | -80.84% |